{"id":"https://openalex.org/W2062407720","doi":"https://doi.org/10.1021/jm980511k","title":"Identification of an Opioid \u03ba Receptor Subtype-Selective N-Substituent for (+)-(3 R ,4 R )-Dimethyl-4-(3-hydroxyphenyl)piperidine","display_name":"Identification of an Opioid \u03ba Receptor Subtype-Selective N-Substituent for (+)-(3 R ,4 R )-Dimethyl-4-(3-hydroxyphenyl)piperidine","publication_year":1998,"publication_date":"1998-11-25","ids":{"openalex":"https://openalex.org/W2062407720","doi":"https://doi.org/10.1021/jm980511k","mag":"2062407720","pmid":"https://pubmed.ncbi.nlm.nih.gov/9857089"},"language":"en","primary_location":{"id":"doi:10.1021/jm980511k","doi":"https://doi.org/10.1021/jm980511k","is_oa":false,"landing_page_url":"https://doi.org/10.1021/jm980511k","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058616888","display_name":"James B. Thomas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James B. Thomas","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068435772","display_name":"Michael J. Fall","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael J. Fall","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066956511","display_name":"Julie Cooper","orcid":"https://orcid.org/0000-0001-9389-9139","observed_orcids":["https://orcid.org/0000-0001-9389-9139"]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julie B. Cooper","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103446078","display_name":"Richard B. Rothman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard B. Rothman","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015241846","display_name":"S. Wayne Mascarella","orcid":"https://orcid.org/0000-0003-0092-8178","observed_orcids":["https://orcid.org/0000-0003-0092-8178"]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Wayne Mascarella","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285","Cntr Drug Discovery"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]},{"raw_affiliation_string":"Cntr Drug Discovery","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103501601","display_name":"Heng Xu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Heng Xu","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012476234","display_name":"John S. Partilla","orcid":"https://orcid.org/0000-0003-1023-5631","observed_orcids":["https://orcid.org/0000-0003-1023-5631"]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John S. Partilla","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014962738","display_name":"Christina M. Dersch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christina M. Dersch","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051052063","display_name":"Karen B. McCullough","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karen B. McCullough","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011158918","display_name":"Buddy E. Cantrell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Buddy E. Cantrell","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109128143","display_name":"Dennis M. Zimmerman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dennis M. Zimmerman","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112366469","display_name":"F. Ivy Carroll","orcid":"https://orcid.org/0000-0001-9510-765X","observed_orcids":["https://orcid.org/0000-0001-9510-765X"]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]},{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I180297670","display_name":"RTI International","ror":"https://ror.org/052tfza37","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"F. Ivy Carroll","raw_affiliation_strings":["Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285","Cntr Drug Discovery"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, North Carolina 27709, Clinical Psychopharmacology Section, NIDA Addiction Research Section, P.O. Box 5180, Building C, 4980 Eastern Avenue, Baltimore, Maryland 21224, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285","institution_ids":["https://openalex.org/I1327069482","https://openalex.org/I168537998","https://openalex.org/I180297670"]},{"raw_affiliation_string":"Cntr Drug Discovery","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":0.7909,"has_fulltext":false,"cited_by_count":53,"citation_normalized_percentile":{"value":0.67367596,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"41","issue":"26","first_page":"5188","last_page":"5197"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10814","display_name":"Neuropeptides and Animal Physiology","score":0.7871000170707703,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10814","display_name":"Neuropeptides and Animal Physiology","score":0.7871000170707703,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10911","display_name":"Chemical Synthesis and Analysis","score":0.1273999959230423,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11178","display_name":"Receptor Mechanisms and Signaling","score":0.051500000059604645,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/kappa-opioid-receptor","display_name":"kappa opioid receptor","score":0.9679999947547913},{"id":"https://openalex.org/keywords/opioid-receptor-selectivity","display_name":"opioid receptor selectivity","score":0.7080000042915344},{"id":"https://openalex.org/keywords/structure-activity-relationship","display_name":"structure-activity relationship","score":0.6729999780654907},{"id":"https://openalex.org/keywords/mu-opioid-receptor","display_name":"mu-opioid receptor","score":0.7279999852180481},{"id":"https://openalex.org/keywords/delta-opioid-receptor","display_name":"delta opioid receptor","score":0.7409999966621399},{"id":"https://openalex.org/keywords/opioid-antagonists","display_name":"opioid antagonists","score":0.5},{"id":"https://openalex.org/keywords/chemical-diversity","display_name":"chemical diversity","score":0.36399999260902405}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.9386546611785889},{"id":"https://openalex.org/C2781462491","wikidata":"https://www.wikidata.org/wiki/Q410234","display_name":"Piperidine","level":2,"score":0.8545729517936707},{"id":"https://openalex.org/C2778689049","wikidata":"https://www.wikidata.org/wiki/Q898422","display_name":"Substituent","level":2,"score":0.8458651304244995},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.591035783290863},{"id":"https://openalex.org/C2781063702","wikidata":"https://www.wikidata.org/wiki/Q427523","display_name":"Opioid","level":3,"score":0.5443893671035767},{"id":"https://openalex.org/C2779886867","wikidata":"https://www.wikidata.org/wiki/Q421797","display_name":"Opioid receptor","level":4,"score":0.5019261837005615},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3236493468284607},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.29850655794143677},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.15967562794685364},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001667","descriptor_name":"Binding, Competitive","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004353","descriptor_name":"Drug Evaluation, Preclinical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006168","descriptor_name":"Guinea Pigs","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007783","descriptor_name":"Lactones","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D007783","descriptor_name":"Lactones","qualifier_ui":"Q000302","qualifier_name":"isolation & purification","is_major_topic":false},{"descriptor_ui":"D007783","descriptor_name":"Lactones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D007783","descriptor_name":"Lactones","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D008024","descriptor_name":"Ligands","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009292","descriptor_name":"Narcotic Antagonists","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D009292","descriptor_name":"Narcotic Antagonists","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009292","descriptor_name":"Narcotic Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D009292","descriptor_name":"Narcotic Antagonists","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D011699","descriptor_name":"Putamen","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D011699","descriptor_name":"Putamen","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D011869","descriptor_name":"Radioligand Assay","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017450","descriptor_name":"Receptors, Opioid, mu","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D017473","descriptor_name":"Receptors, Opioid, kappa","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D066298","descriptor_name":"In Vitro Techniques","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1021/jm980511k","doi":"https://doi.org/10.1021/jm980511k","is_oa":false,"landing_page_url":"https://doi.org/10.1021/jm980511k","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:9857089","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9857089","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medicinal chemistry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[],"study_designs":[],"awards":[{"id":"https://openalex.org/G3861717303","display_name":null,"funder_award_id":"DA 09045","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"},{"id":"https://openalex.org/G6365479704","display_name":"Selective Opioid Antagonists as Medications for Drug Abuse","funder_award_id":"R01DA009045","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"}],"funders":[{"id":"https://openalex.org/F4320337347","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":14,"referenced_works":["https://openalex.org/W1926302616","https://openalex.org/W1980450634","https://openalex.org/W1987914647","https://openalex.org/W2001528480","https://openalex.org/W2011715860","https://openalex.org/W2016634408","https://openalex.org/W2037536875","https://openalex.org/W2038322363","https://openalex.org/W2053547251","https://openalex.org/W2053570401","https://openalex.org/W2081965953","https://openalex.org/W2089571021","https://openalex.org/W2949678656","https://openalex.org/W4206402978"],"related_works":["https://openalex.org/W1996795014","https://openalex.org/W2056132478","https://openalex.org/W1980100970","https://openalex.org/W2617693854","https://openalex.org/W2015615284","https://openalex.org/W1994823738","https://openalex.org/W2087848507","https://openalex.org/W1973235666","https://openalex.org/W1968230368","https://openalex.org/W1985171304"],"abstract_inverted_index":{"A":[0],"three-component":[1],"library":[2],"of":[3,35,53,65,84,136,138,164,188],"compounds":[4,16,67],"was":[5,172],"prepared":[6],"in":[7,68,148,167,175],"parallel":[8],"using":[9],"multiple":[10],"simultaneous":[11],"solution-phase":[12],"synthetic":[13],"methodology.":[14],"The":[15,38,162],"were":[17,58],"biased":[18],"toward":[19],"opioid":[20,30,75,88,113,193,201],"receptor":[21,76,89,114,127,143,153,202],"antagonist":[22,204],"activity":[23],"by":[24],"incorporating":[25],"(+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine":[26],"(a":[27],"potent,":[28],"nonselective":[29],"pure":[31,203],"antagonist)":[32],"as":[33,198],"one":[34],"the":[36,73,82,125,129,141,151,156,168,176,209],"monomers.":[37],"other":[39],"two":[40],"monomers,":[41],"which":[42],"included":[43],"N-substituted":[44],"or":[45],"unsubstituted":[46],"Boc-protected":[47],"amino":[48],"acids":[49],"and":[50,105,116,144],"a":[51,85,133,199],"range":[52],"substituted":[54],"aryl":[55],"carboxylic":[56],"acids,":[57],"selected":[59],"to":[60,81,111,121,155,180,183],"add":[61],"chemical":[62],"diversity.":[63],"Screening":[64],"these":[66],"competitive":[69],"binding":[70,170,187],"experiments":[71,171],"with":[72,205],"kappa":[74,87,126,152],"selective":[77,90],"ligand":[78],"[3H]U69,593":[79],"led":[80],"discovery":[83],"novel":[86],"ligand,":[91,158],"N-\u00bf(2'S)-[3-(4-hydroxyphenyl)propanamido]-3'-methylbutyl\u00bf-(3R,":[92],"4R)-dimethyl-4-(3-hydroxyphenyl)piperidine":[93,160],"(8,":[94],"RTI-5989-29).":[95],"Additional":[96],"structure-activity":[97],"relationship":[98],"studies":[99],"suggested":[100],"that":[101,108],"8":[102,139,196],"possesses":[103],"lipophilic":[104],"hydrogen-bonding":[106],"sites":[107,119],"are":[109],"important":[110],"its":[112,181],"potency":[115],"selectivity.":[117],"These":[118],"appear":[120],"exist":[122],"predominantly":[123],"within":[124],"since":[128],"selectivity":[130,165],"arises":[131],"from":[132],"530-fold":[134],"loss":[135],"affinity":[137,149,207],"for":[140,150,208],"mu":[142],"an":[145],"18-fold":[146],"increase":[147],"relative":[154],"mu-selective":[157],"(+)-N-[trans-4-phenyl-2-butenyl]-(3R,":[159],"(5a).":[161],"degree":[163],"observed":[166,174],"radioligand":[169],"not":[173],"functional":[177],"assay.":[178],"According":[179],"ability":[182],"inhibit":[184],"agonist":[185],"stimulated":[186],"[35S]GTPgammaS":[189],"at":[190],"all":[191],"three":[192],"receptors,":[194],"compound":[195],"behaves":[197],"mu/kappa":[200],"negligible":[206],"delta":[210],"receptor.":[211]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":5}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}